1. Scrip

Verdiva Bio Launched With Record Series A To Advance Weekly Oral GLP-1

 
• By Andrew McConaghie

Investor appetite for obesity-based biotechs shows no sign of waning as UK-based Verdiva Bio launches with a $411m series A and ambitions to develop an oral, weekly GLP-1 product.

Scales obesity
• Source: Shutterstock

Novo Nordisk and Eli Lilly may command the injectable obesity drug market but they have a new threat to their oral GLP-1 candidates in the form of Verdiva Bio.

It was launched on 9 January with an eyebrow-raising $411m oversubscribed series A – a record-breaking haul for any UK or EU initial fundraising round, according to CEO Khurem Farooq. The firm has licensed from China’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip

More from Business

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.